Detect residual disease before it spreads
Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act
Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act
Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act
Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act
Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act
In the clinical research setting, Signatera ctDNA analysis could be used as a tool for predicting the likelihood of relapse, monitoring response to neoadjuvant treatment, detecting minimal residual disease, monitoring for recurrence after adjuvant treatment, and monitoring for treatment efficacy and resistance.1-5
Well-designed and successful clinical trials could facilitate earlier “go/no go” decision-making, which may ultimately enhance the R&D pipeline productivity and impact label expansion of approved oncology drugs to the adjuvant setting.
Signatera ctDNA assay can be used to optimize aspects of clinical trial design that could increase the probability of trial success or accelerate trial completion, such as:
Collaborators | Tumor type | Study goal | Patients studied |
---|---|---|---|
Institut Jules Bordet |
|
Correlate results of ctDNA with clinical outcomes, including pathological response and event- free survival | Non-metastatic, post-neoadjuvant therapy and post-surgery |
Fox Chase Cancer Center |
|
Determine relationship between kidney cancer genetic profiles and prognosis with ctDNA | Patients with kidney cancer who recurred or did not recur after ≥3 years |
Neon Therapeutics |
|
Use of ctDNA to assess treatment response to the NEO-PV-01 personal cancer vaccine in combination with pembrolizumab and a chemotherapy regimen of pemetrexed and carboplatin in the NT-002 trial | Untreated patients with advanced or metastatic non-squamous non-small cell lung cancer |
Princess Margaret Cancer Centre |
|
Assess patient response to immunotherapy in the metastatic setting by detecting ctDNA in the blood | Patients with advanced cancers (including head and neck, triple-negative breast, melanoma, and ovarian) treated with single-agent pembrolizumab as part of the INSPIRE trial |
Collaborators | Tumor type | Study goal | Patients studied |
---|---|---|---|
Institut Jules Bordet |
|
Correlate results of ctDNA with clinical outcomes, including pathological response and event- free survival | Non-metastatic, post-neoadjuvant therapy and post-surgery |
Fox Chase Cancer Center |
|
Determine relationship between kidney cancer genetic profiles and prognosis with ctDNA | Patients with kidney cancer who recurred or did not recur after ≥3 years |
Neon Therapeutics |
|
Use of ctDNA to assess treatment response to the NEO-PV-01 personal cancer vaccine in combination with pembrolizumab and a chemotherapy regimen of pemetrexed and carboplatin in the NT-002 trial | Untreated patients with advanced or metastatic non-squamous non-small cell lung cancer |
Princess Margaret Cancer Centre |
|
Assess patient response to immunotherapy in the metastatic setting by detecting ctDNA in the blood | Patients with advanced cancers (including head and neck, triple-negative breast, melanoma, and ovarian) treated with single-agent pembrolizumab as part of the INSPIRE trial |
Collaborators | Tumor type | Study goal | Patients studied |
---|---|---|---|
Institut Jules Bordet |
|
Correlate results of ctDNA with clinical outcomes, including pathological response and event- free survival | Non-metastatic, post-neoadjuvant therapy and post-surgery |
Fox Chase Cancer Center |
|
Determine relationship between kidney cancer genetic profiles and prognosis with ctDNA | Patients with kidney cancer who recurred or did not recur after ≥3 years |
Neon Therapeutics |
|
Use of ctDNA to assess treatment response to the NEO-PV-01 personal cancer vaccine in combination with pembrolizumab and a chemotherapy regimen of pemetrexed and carboplatin in the NT-002 trial | Untreated patients with advanced or metastatic non-squamous non-small cell lung cancer |
Princess Margaret Cancer Centre |
|
Assess patient response to immunotherapy in the metastatic setting by detecting ctDNA in the blood | Patients with advanced cancers (including head and neck, triple-negative breast, melanoma, and ovarian) treated with single-agent pembrolizumab as part of the INSPIRE trial |
Collaborators | Tumor type | Study goal | Patients studied |
---|---|---|---|
Institut Jules Bordet |
|
Correlate results of ctDNA with clinical outcomes, including pathological response and event- free survival | Non-metastatic, post-neoadjuvant therapy and post-surgery |
Fox Chase Cancer Center |
|
Determine relationship between kidney cancer genetic profiles and prognosis with ctDNA | Patients with kidney cancer who recurred or did not recur after ≥3 years |
Neon Therapeutics |
|
Use of ctDNA to assess treatment response to the NEO-PV-01 personal cancer vaccine in combination with pembrolizumab and a chemotherapy regimen of pemetrexed and carboplatin in the NT-002 trial | Untreated patients with advanced or metastatic non-squamous non-small cell lung cancer |
Princess Margaret Cancer Centre |
|
Assess patient response to immunotherapy in the metastatic setting by detecting ctDNA in the blood | Patients with advanced cancers (including head and neck, triple-negative breast, melanoma, and ovarian) treated with single-agent pembrolizumab as part of the INSPIRE trial |
In 2019 Natera plans to sponsor prospective, multicenter BESPOKE Studies, which will examine the clinical utility of the Signatera™ ctDNA test for monitoring recurrence and guiding treatment decisions in patients with solid tumors.
Contact us to learn more about collaborating with Natera in the BESPOKE Studies.
Signatera Billing and Customer Care: 650.489.9050
Hours of operation: Monday - Friday 7am-7pm CST and Saturday 8am-5pm CST
Email: signateracc@natera.com
References
Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.
Reinert T, Henriksen TV, Rasmussen MH, et al. Serial Circulating Tumor DNA Analysis for Detection of Residual Disease, Assessment of Adjuvant Therapy Efficacy and for Early Recurrence Detection in Colorectal Cancer. Poster presented at: European Society for Medical Oncology Annual Congress; October 21, 2018; Munich, Germany. Abstract 456PD.
Birkenkamp-Demtröder K, Christensen E, Sethi H, et al. Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer for Surveillance and Therapeutic Efficacy Monitoring. Poster presented at: European Society for Medical Oncology Annual Congress; October 20, 2018; Munich, Germany. Abstract 86P.
Coombes RC, Armstrong A, Ahmed S. Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumor DNA (ctDNA) antedates overt metastatic recurrence. Poster presented at: San Antonio Breast Cancer Symposium; December 7, 2018. San Antonio, TX. Abstract 1266.
Magbanua MJM, Brown-Swigart L, Hirst GL. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 trial. Poster presented at: San Antonio Breast Cancer Symposium; December 5, 2018. San Antonio, TX. Abstract 1259.